Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis

Background Stereotactic body radiotherapy (SBRT) is gaining wider adoption for prostate cancer management but there remain significant toxicity risks when delivering prostate SBRT with standard techniques. Magnetic resonance‐guided daily adaptive SBRT (MRg‐A‐SBRT) offers technological advantages in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2023-10, Vol.129 (19), p.3044-3052
Hauptverfasser: Leeman, Jonathan E., Shin, Kee‐Young, Chen, Yu‐Hui, Mak, Raymond H., Nguyen, Paul L., D’Amico, Anthony V., Martin, Neil E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3052
container_issue 19
container_start_page 3044
container_title Cancer
container_volume 129
creator Leeman, Jonathan E.
Shin, Kee‐Young
Chen, Yu‐Hui
Mak, Raymond H.
Nguyen, Paul L.
D’Amico, Anthony V.
Martin, Neil E.
description Background Stereotactic body radiotherapy (SBRT) is gaining wider adoption for prostate cancer management but there remain significant toxicity risks when delivering prostate SBRT with standard techniques. Magnetic resonance‐guided daily adaptive SBRT (MRg‐A‐SBRT) offers technological advantages in precision of radiation dose delivery, but the toxicity profile associated with MRg‐A‐SBRT compared to more standardly used fiducial or computed tomography‐guided non‐adaptive prostate SBRT (CT‐SBRT) remains unknown. Methods A meta‐analysis to compare acute toxicity rates associated with MRg‐A‐SBRT and CT‐SBRT for prostate cancer was performed in compliance with PRISMA guidelines. MEDLINE (PubMed) and Google Scholar were searched for prospective studies of prostate SBRT that were published between January 1, 2018 and August 31, 2022. Random effects and fixed effects models were used to estimate pooled toxicity rates, and meta‐regression was performed to compare toxicity between MRg‐A‐SBRT and CT‐SBRT study groups. Results Twenty‐nine prospective studies were identified that met the inclusion criteria and included a total of 2547 patients. The pooled estimates for acute grade 2 or higher (G2+) genitourinary (GU) and gastrointestinal (GI) toxicity for MRg‐A‐SBRT were 16% (95% confidence interval [CI], 10%–24%) and 4% (95% CI, 2%–7%) and for CT‐SBRT they were 28% (95% CI, 23%‐33%) and 9% (95% CI, 6%‐12%), respectively. On meta‐regression, the odds ratios for acute G2+ GU and GI toxicities comparing MRg‐A‐SBRT and CT‐SBRT were 0.56 (95% CI, 0.33–0.97, p = .04) and 0.40 (95% CI, 0.17–0.96, p = .04), respectively. Conclusion MRg‐A‐SBRT is associated with a significantly reduced risk of acute G2+ GU or GI toxicity compared to CT‐SBRT. Longer follow‐up will be needed to evaluate late toxicity and disease control outcomes. Plain language summary Magnetic resonance imaging‐guided daily adaptive prostate stereotactic radiation (MRg‐A‐SBRT) is a treatment that may allow for delivery of prostate radiation more precisely than other radiotherapy techniques, but it is unknown whether this reduces side effects compared to standardly used computed tomography‐guided SBRT (CT‐SBRT). In this systematic review and meta‐analysis combining data from 29 clinical trials including 2547 patients, it was found that the risk of short‐term urinary side effects was reduced by 44% and the risk of short‐term bowel side effects was reduced by 60% with MRg‐A‐SBRT compared to CT‐SBRT. This meta‐anal
doi_str_mv 10.1002/cncr.34836
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2841401302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2841401302</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3576-edbf0881b36bb4df635ba0a173cb146ebe97254e45e69763f68429b96589303b3</originalsourceid><addsrcrecordid>eNp9kc-K1TAUh4MoznV04wNIwI0MdEyaNG3dXS6OCoOCKLgr-XN6J0Pb1CS9Y3c-go_gs_gIPoJPYjodR3DhKpzwnS8n54fQY0pOKSH5cz1of8p4xcQdtKGkLjNCeX4XbQghVVZw9ukIPQjhMpVlXrD76IiVvCpEXW7Qz62eIuDovlht44y160fpbXADdi3u5X6AaDX2kG7koOHX12_7yRowWBo5RnsAfAAfpoBbayZtZYedv7YkrUne3u29HC_mv42DG1Jx2z56F6JMM4QIHlyUenlQOTNjL4118QKSYH6Btz--hzlBvVwnOli4wnIwuIcoF-MguznY8BDda2UX4NHNeYw-nr38sHudnb979Wa3Pc80K0qRgVEtqSqqmFCKm1awQkkiacm0olyAgjptiwMvIG1KsFZUPK9VLYqqZoQpdoyerd70g88ThNj0NmjoOjmAm0KTV5xyQhnJE_r0H_TSTT7Nu1BFLWjBRZWok5XSaSXBQ9uM3vbSzw0lzZJ0syTdXCed4Cc3ykn1YG7RP9EmgK7Ale1g_o-q2b3dvV-lvwGWLb7B</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2859615468</pqid></control><display><type>article</type><title>Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis</title><source>Wiley Online Library website</source><source>Free E-Journal (出版社公開部分のみ)</source><source>Wiley Online Library (Online service)</source><source>Alma/SFX Local Collection</source><creator>Leeman, Jonathan E. ; Shin, Kee‐Young ; Chen, Yu‐Hui ; Mak, Raymond H. ; Nguyen, Paul L. ; D’Amico, Anthony V. ; Martin, Neil E.</creator><creatorcontrib>Leeman, Jonathan E. ; Shin, Kee‐Young ; Chen, Yu‐Hui ; Mak, Raymond H. ; Nguyen, Paul L. ; D’Amico, Anthony V. ; Martin, Neil E.</creatorcontrib><description>Background Stereotactic body radiotherapy (SBRT) is gaining wider adoption for prostate cancer management but there remain significant toxicity risks when delivering prostate SBRT with standard techniques. Magnetic resonance‐guided daily adaptive SBRT (MRg‐A‐SBRT) offers technological advantages in precision of radiation dose delivery, but the toxicity profile associated with MRg‐A‐SBRT compared to more standardly used fiducial or computed tomography‐guided non‐adaptive prostate SBRT (CT‐SBRT) remains unknown. Methods A meta‐analysis to compare acute toxicity rates associated with MRg‐A‐SBRT and CT‐SBRT for prostate cancer was performed in compliance with PRISMA guidelines. MEDLINE (PubMed) and Google Scholar were searched for prospective studies of prostate SBRT that were published between January 1, 2018 and August 31, 2022. Random effects and fixed effects models were used to estimate pooled toxicity rates, and meta‐regression was performed to compare toxicity between MRg‐A‐SBRT and CT‐SBRT study groups. Results Twenty‐nine prospective studies were identified that met the inclusion criteria and included a total of 2547 patients. The pooled estimates for acute grade 2 or higher (G2+) genitourinary (GU) and gastrointestinal (GI) toxicity for MRg‐A‐SBRT were 16% (95% confidence interval [CI], 10%–24%) and 4% (95% CI, 2%–7%) and for CT‐SBRT they were 28% (95% CI, 23%‐33%) and 9% (95% CI, 6%‐12%), respectively. On meta‐regression, the odds ratios for acute G2+ GU and GI toxicities comparing MRg‐A‐SBRT and CT‐SBRT were 0.56 (95% CI, 0.33–0.97, p = .04) and 0.40 (95% CI, 0.17–0.96, p = .04), respectively. Conclusion MRg‐A‐SBRT is associated with a significantly reduced risk of acute G2+ GU or GI toxicity compared to CT‐SBRT. Longer follow‐up will be needed to evaluate late toxicity and disease control outcomes. Plain language summary Magnetic resonance imaging‐guided daily adaptive prostate stereotactic radiation (MRg‐A‐SBRT) is a treatment that may allow for delivery of prostate radiation more precisely than other radiotherapy techniques, but it is unknown whether this reduces side effects compared to standardly used computed tomography‐guided SBRT (CT‐SBRT). In this systematic review and meta‐analysis combining data from 29 clinical trials including 2547 patients, it was found that the risk of short‐term urinary side effects was reduced by 44% and the risk of short‐term bowel side effects was reduced by 60% with MRg‐A‐SBRT compared to CT‐SBRT. This meta‐analysis of 29 prostate stereotactic body radiotherapy (SBRT) studies including 2547 patients found a reduction in the risk of acute urinary and gastrointestinal side effects with magnetic resonance‐guided adaptive SBRT compared to standard computed tomography‐guided SBRT.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.34836</identifier><identifier>PMID: 37485697</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Acute toxicity ; Adaptive control ; Clinical trials ; Computed tomography ; Confidence intervals ; Disease control ; Magnetic resonance imaging ; Meta-analysis ; MR‐guided ; Oncology ; Patients ; prospective studies ; Prostate cancer ; Radiation ; Radiation dosage ; Radiation therapy ; Risk management ; SBRT ; Search engines ; Side effects ; Statistical analysis ; Systematic review ; Tomography ; Toxic diseases ; Toxicity</subject><ispartof>Cancer, 2023-10, Vol.129 (19), p.3044-3052</ispartof><rights>2023 American Cancer Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3576-edbf0881b36bb4df635ba0a173cb146ebe97254e45e69763f68429b96589303b3</citedby><cites>FETCH-LOGICAL-c3576-edbf0881b36bb4df635ba0a173cb146ebe97254e45e69763f68429b96589303b3</cites><orcidid>0000-0003-4539-0762</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.34836$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.34836$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37485697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leeman, Jonathan E.</creatorcontrib><creatorcontrib>Shin, Kee‐Young</creatorcontrib><creatorcontrib>Chen, Yu‐Hui</creatorcontrib><creatorcontrib>Mak, Raymond H.</creatorcontrib><creatorcontrib>Nguyen, Paul L.</creatorcontrib><creatorcontrib>D’Amico, Anthony V.</creatorcontrib><creatorcontrib>Martin, Neil E.</creatorcontrib><title>Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background Stereotactic body radiotherapy (SBRT) is gaining wider adoption for prostate cancer management but there remain significant toxicity risks when delivering prostate SBRT with standard techniques. Magnetic resonance‐guided daily adaptive SBRT (MRg‐A‐SBRT) offers technological advantages in precision of radiation dose delivery, but the toxicity profile associated with MRg‐A‐SBRT compared to more standardly used fiducial or computed tomography‐guided non‐adaptive prostate SBRT (CT‐SBRT) remains unknown. Methods A meta‐analysis to compare acute toxicity rates associated with MRg‐A‐SBRT and CT‐SBRT for prostate cancer was performed in compliance with PRISMA guidelines. MEDLINE (PubMed) and Google Scholar were searched for prospective studies of prostate SBRT that were published between January 1, 2018 and August 31, 2022. Random effects and fixed effects models were used to estimate pooled toxicity rates, and meta‐regression was performed to compare toxicity between MRg‐A‐SBRT and CT‐SBRT study groups. Results Twenty‐nine prospective studies were identified that met the inclusion criteria and included a total of 2547 patients. The pooled estimates for acute grade 2 or higher (G2+) genitourinary (GU) and gastrointestinal (GI) toxicity for MRg‐A‐SBRT were 16% (95% confidence interval [CI], 10%–24%) and 4% (95% CI, 2%–7%) and for CT‐SBRT they were 28% (95% CI, 23%‐33%) and 9% (95% CI, 6%‐12%), respectively. On meta‐regression, the odds ratios for acute G2+ GU and GI toxicities comparing MRg‐A‐SBRT and CT‐SBRT were 0.56 (95% CI, 0.33–0.97, p = .04) and 0.40 (95% CI, 0.17–0.96, p = .04), respectively. Conclusion MRg‐A‐SBRT is associated with a significantly reduced risk of acute G2+ GU or GI toxicity compared to CT‐SBRT. Longer follow‐up will be needed to evaluate late toxicity and disease control outcomes. Plain language summary Magnetic resonance imaging‐guided daily adaptive prostate stereotactic radiation (MRg‐A‐SBRT) is a treatment that may allow for delivery of prostate radiation more precisely than other radiotherapy techniques, but it is unknown whether this reduces side effects compared to standardly used computed tomography‐guided SBRT (CT‐SBRT). In this systematic review and meta‐analysis combining data from 29 clinical trials including 2547 patients, it was found that the risk of short‐term urinary side effects was reduced by 44% and the risk of short‐term bowel side effects was reduced by 60% with MRg‐A‐SBRT compared to CT‐SBRT. This meta‐analysis of 29 prostate stereotactic body radiotherapy (SBRT) studies including 2547 patients found a reduction in the risk of acute urinary and gastrointestinal side effects with magnetic resonance‐guided adaptive SBRT compared to standard computed tomography‐guided SBRT.</description><subject>Acute toxicity</subject><subject>Adaptive control</subject><subject>Clinical trials</subject><subject>Computed tomography</subject><subject>Confidence intervals</subject><subject>Disease control</subject><subject>Magnetic resonance imaging</subject><subject>Meta-analysis</subject><subject>MR‐guided</subject><subject>Oncology</subject><subject>Patients</subject><subject>prospective studies</subject><subject>Prostate cancer</subject><subject>Radiation</subject><subject>Radiation dosage</subject><subject>Radiation therapy</subject><subject>Risk management</subject><subject>SBRT</subject><subject>Search engines</subject><subject>Side effects</subject><subject>Statistical analysis</subject><subject>Systematic review</subject><subject>Tomography</subject><subject>Toxic diseases</subject><subject>Toxicity</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kc-K1TAUh4MoznV04wNIwI0MdEyaNG3dXS6OCoOCKLgr-XN6J0Pb1CS9Y3c-go_gs_gIPoJPYjodR3DhKpzwnS8n54fQY0pOKSH5cz1of8p4xcQdtKGkLjNCeX4XbQghVVZw9ukIPQjhMpVlXrD76IiVvCpEXW7Qz62eIuDovlht44y160fpbXADdi3u5X6AaDX2kG7koOHX12_7yRowWBo5RnsAfAAfpoBbayZtZYedv7YkrUne3u29HC_mv42DG1Jx2z56F6JMM4QIHlyUenlQOTNjL4118QKSYH6Btz--hzlBvVwnOli4wnIwuIcoF-MguznY8BDda2UX4NHNeYw-nr38sHudnb979Wa3Pc80K0qRgVEtqSqqmFCKm1awQkkiacm0olyAgjptiwMvIG1KsFZUPK9VLYqqZoQpdoyerd70g88ThNj0NmjoOjmAm0KTV5xyQhnJE_r0H_TSTT7Nu1BFLWjBRZWok5XSaSXBQ9uM3vbSzw0lzZJ0syTdXCed4Cc3ykn1YG7RP9EmgK7Ale1g_o-q2b3dvV-lvwGWLb7B</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Leeman, Jonathan E.</creator><creator>Shin, Kee‐Young</creator><creator>Chen, Yu‐Hui</creator><creator>Mak, Raymond H.</creator><creator>Nguyen, Paul L.</creator><creator>D’Amico, Anthony V.</creator><creator>Martin, Neil E.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4539-0762</orcidid></search><sort><creationdate>20231001</creationdate><title>Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis</title><author>Leeman, Jonathan E. ; Shin, Kee‐Young ; Chen, Yu‐Hui ; Mak, Raymond H. ; Nguyen, Paul L. ; D’Amico, Anthony V. ; Martin, Neil E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3576-edbf0881b36bb4df635ba0a173cb146ebe97254e45e69763f68429b96589303b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute toxicity</topic><topic>Adaptive control</topic><topic>Clinical trials</topic><topic>Computed tomography</topic><topic>Confidence intervals</topic><topic>Disease control</topic><topic>Magnetic resonance imaging</topic><topic>Meta-analysis</topic><topic>MR‐guided</topic><topic>Oncology</topic><topic>Patients</topic><topic>prospective studies</topic><topic>Prostate cancer</topic><topic>Radiation</topic><topic>Radiation dosage</topic><topic>Radiation therapy</topic><topic>Risk management</topic><topic>SBRT</topic><topic>Search engines</topic><topic>Side effects</topic><topic>Statistical analysis</topic><topic>Systematic review</topic><topic>Tomography</topic><topic>Toxic diseases</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leeman, Jonathan E.</creatorcontrib><creatorcontrib>Shin, Kee‐Young</creatorcontrib><creatorcontrib>Chen, Yu‐Hui</creatorcontrib><creatorcontrib>Mak, Raymond H.</creatorcontrib><creatorcontrib>Nguyen, Paul L.</creatorcontrib><creatorcontrib>D’Amico, Anthony V.</creatorcontrib><creatorcontrib>Martin, Neil E.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leeman, Jonathan E.</au><au>Shin, Kee‐Young</au><au>Chen, Yu‐Hui</au><au>Mak, Raymond H.</au><au>Nguyen, Paul L.</au><au>D’Amico, Anthony V.</au><au>Martin, Neil E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>129</volume><issue>19</issue><spage>3044</spage><epage>3052</epage><pages>3044-3052</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Background Stereotactic body radiotherapy (SBRT) is gaining wider adoption for prostate cancer management but there remain significant toxicity risks when delivering prostate SBRT with standard techniques. Magnetic resonance‐guided daily adaptive SBRT (MRg‐A‐SBRT) offers technological advantages in precision of radiation dose delivery, but the toxicity profile associated with MRg‐A‐SBRT compared to more standardly used fiducial or computed tomography‐guided non‐adaptive prostate SBRT (CT‐SBRT) remains unknown. Methods A meta‐analysis to compare acute toxicity rates associated with MRg‐A‐SBRT and CT‐SBRT for prostate cancer was performed in compliance with PRISMA guidelines. MEDLINE (PubMed) and Google Scholar were searched for prospective studies of prostate SBRT that were published between January 1, 2018 and August 31, 2022. Random effects and fixed effects models were used to estimate pooled toxicity rates, and meta‐regression was performed to compare toxicity between MRg‐A‐SBRT and CT‐SBRT study groups. Results Twenty‐nine prospective studies were identified that met the inclusion criteria and included a total of 2547 patients. The pooled estimates for acute grade 2 or higher (G2+) genitourinary (GU) and gastrointestinal (GI) toxicity for MRg‐A‐SBRT were 16% (95% confidence interval [CI], 10%–24%) and 4% (95% CI, 2%–7%) and for CT‐SBRT they were 28% (95% CI, 23%‐33%) and 9% (95% CI, 6%‐12%), respectively. On meta‐regression, the odds ratios for acute G2+ GU and GI toxicities comparing MRg‐A‐SBRT and CT‐SBRT were 0.56 (95% CI, 0.33–0.97, p = .04) and 0.40 (95% CI, 0.17–0.96, p = .04), respectively. Conclusion MRg‐A‐SBRT is associated with a significantly reduced risk of acute G2+ GU or GI toxicity compared to CT‐SBRT. Longer follow‐up will be needed to evaluate late toxicity and disease control outcomes. Plain language summary Magnetic resonance imaging‐guided daily adaptive prostate stereotactic radiation (MRg‐A‐SBRT) is a treatment that may allow for delivery of prostate radiation more precisely than other radiotherapy techniques, but it is unknown whether this reduces side effects compared to standardly used computed tomography‐guided SBRT (CT‐SBRT). In this systematic review and meta‐analysis combining data from 29 clinical trials including 2547 patients, it was found that the risk of short‐term urinary side effects was reduced by 44% and the risk of short‐term bowel side effects was reduced by 60% with MRg‐A‐SBRT compared to CT‐SBRT. This meta‐analysis of 29 prostate stereotactic body radiotherapy (SBRT) studies including 2547 patients found a reduction in the risk of acute urinary and gastrointestinal side effects with magnetic resonance‐guided adaptive SBRT compared to standard computed tomography‐guided SBRT.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37485697</pmid><doi>10.1002/cncr.34836</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4539-0762</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2023-10, Vol.129 (19), p.3044-3052
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_2841401302
source Wiley Online Library website; Free E-Journal (出版社公開部分のみ); Wiley Online Library (Online service); Alma/SFX Local Collection
subjects Acute toxicity
Adaptive control
Clinical trials
Computed tomography
Confidence intervals
Disease control
Magnetic resonance imaging
Meta-analysis
MR‐guided
Oncology
Patients
prospective studies
Prostate cancer
Radiation
Radiation dosage
Radiation therapy
Risk management
SBRT
Search engines
Side effects
Statistical analysis
Systematic review
Tomography
Toxic diseases
Toxicity
title Acute toxicity comparison of magnetic resonance‐guided adaptive versus fiducial or computed tomography‐guided non‐adaptive prostate stereotactic body radiotherapy: A systematic review and meta‐analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A49%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20toxicity%20comparison%20of%20magnetic%20resonance%E2%80%90guided%20adaptive%20versus%20fiducial%20or%20computed%20tomography%E2%80%90guided%20non%E2%80%90adaptive%20prostate%20stereotactic%20body%20radiotherapy:%20A%C2%A0systematic%20review%20and%20meta%E2%80%90analysis&rft.jtitle=Cancer&rft.au=Leeman,%20Jonathan%20E.&rft.date=2023-10-01&rft.volume=129&rft.issue=19&rft.spage=3044&rft.epage=3052&rft.pages=3044-3052&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.34836&rft_dat=%3Cproquest_cross%3E2841401302%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2859615468&rft_id=info:pmid/37485697&rfr_iscdi=true